Advanced imaging technology reveals pulsed hormone release regulates gene transcription

Using advanced microscopic imaging technology, CCR investigators have correlated a pulsed pattern of hormone release with bursts of transcription, the process in which the genetic information encoded by DNA is written into RNA. They are the first researchers to observe this process at a gene-specific level. Read more...

Remi Adelaiye-Ogala with Nigerian flag

The Center for Cancer Research celebrates National Postdoc Appreciation Week

Sep 16, 2019

This week, we’re celebrating National Postdoc Appreciation Week. Our postdocs come from around the world to train at the Center for Cancer Research, and they are vital members of our cancer research community. Hear from some of our international postdocs on why they came here to train, and learn more about our training programs. Read more...

The Center for Cancer Research celebrates National Postdoc Appreciation Week
Karlyne Reilly

Karlyne Reilly discusses childhood cancer on BioMedCentral

Sep 16, 2019

Karlyne M. Reilly, Ph.D., Senior Associate Scientist in the Pediatric Oncology Branch, recently wrote a blog for BioMedCentral. In the blog, Dr. Reilly addresses both the difficulties and the importance of accessing and collecting data from childhood cancer clinical trials and initiatives, such as MyPART, to help improve childhood cancer research in the future.  Read more...

Karlyne Reilly discusses childhood cancer on BioMedCentral
3D structure of a melanoma cell

Tumor composition of melanoma indicates potential responses to immunotherapy

Sep 13, 2019

The number of genetic mutations in a tumor is thought to influence how well melanoma may respond to immunotherapy, but new research in mice and supported by preliminary human data reveals that the diversity of mutations within a tumor may be a better indicator of response to therapy. Read more...

Dom and camp counselors

Neurofibromatosis type 1 patient attends Camp Fantastic for the first time

Sep 12, 2019

Thirteen-year-old Dom was diagnosed with neurofibromatosis type 1 at birth. Because of Dom’s diagnosis, he hasn’t always had the opportunity to do the things the average teenager does, but his first year at Camp Fantastic changed that. Camp Fantastic, an annual week-long camp for pediatric cancer patients and survivors, gave Dom the opportunity to try lots of new things and some familiar ones in a setting of support, safety and friendship. Read more...

NIH IRP Speaking of Science

Michael Gottesman and Ira Pastan featured in NIH Intramural Research Program podcast

Sep 12, 2019

Michael Gottesman, M.D., Chief of the Laboratory of Cell Biology, and Ira Pastan, M.D., Co-Chief of the Laboratory of Molecular Biology, were recently featured in the NIH IRP podcast Speaking of Science. In the podcast, Dr. Gottesman and Dr. Pastan discussed how their research and discoveries have helped effectively treat cancer in order to improve and save potentially millions of lives.  Read more...

Michael Gottesman and Ira Pastan featured in NIH Intramural Research Program podcast
Lori Wiener

Lori Wiener selected as NYU Alumni Changemaker

Sep 10, 2019

Lori Wiener, Ph.D., DCSW, LCSW-C, Senior Associate Scientist in the Pediatric Oncology Branch, has been selected as a 2019 NYU Alumni Changemaker. Changemakers are selected by the NYU Alumni Association Board for their ability to reduce suffering, bring hope to the marginalized and save lives.  Read more...

Lori Wiener selected as NYU Alumni Changemaker
Chart on how CAR T-cell therapy works

FDA grants breakthrough therapy designation for new CAR T-cell therapy for B-cell acute lymphoblastic leukemia

Sep 10, 2019

In August 2019, the U.S. Food and Drug Administration granted breakthrough therapy designation to an experimental immunotherapy being developed in the Center for Cancer Research (CCR) for the treatment of B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The designation will advance CCR’s development and testing of an immunotherapy for children and young adults whose B-cell ALL is resistant to CD19-targeted immunotherapies.  Read more...

Follicular lymphoma

Clinical trial evaluates dual drug therapy for untreated follicular lymphoma

Sep 5, 2019

Follicular lymphoma (FL) is a cancer of white blood cells (B cells) that help your body fight infections. Investigators are leading a clinical trial at the NIH Clinical Center to see if a combination therapy can slow the growth of FL in patients who have not received prior treatment.  Read more...

Steve Rosenberg

Steve Rosenberg receives 2019 Edogawa NICHE Prize

Sep 4, 2019

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, has received the 2019 Edogawa NICHE Prize. Dr. Rosenberg was recognized for his pioneering work in developing effective adoptive immunotherapies and genetically modified T cells, which has heralded the birth of a new chapter in the fight against cancer. Read more...

Steve Rosenberg receives 2019 Edogawa NICHE Prize
James Kochenderfer

James Kochenderfer named finalist for 2019 FNIH Trailblazer Prize for Clinician-Scientists

Sep 4, 2019

James N. Kochenderfer, M.D., Investigator in the Surgery Branch, has been selected as a finalist for the Foundation for the National Institutes of Health (FNIH) Trailblazer Prize for Clinician-Scientists. He is nominated for developing immunotherapies that leverage chimeric antigen receptor (CAR) T cells to treat blood cancers, including lymphoma and multiple myeloma. The winner of the Trailblazer Prize will be announced October 23, 2019. Read more...

James Kochenderfer named finalist for 2019 FNIH Trailblazer Prize for Clinician-Scientists

Pages